Major interaction on record — check this product against your medications before combining. Check your meds →
Dietary supplement

Cystistatin Ingredients & Drug Interactions

by Ortho Molecular Products

Capsule Category: Other Combinations
Most serious interaction: Major
The interaction bottom line Most serious interaction: Major

Cystistatin is a dietary supplement by Ortho Molecular Products with 5 active ingredients. Its ingredients are commonly taken for cough and sore throat, dry mouth and throat irritation, digestive upset and heartburn.Based on those ingredients, 2,180 medications have a known interaction with it, the most serious rated major. The ingredients most likely to interact are Marshmallow, Berberine Hydrochloride Hydrate, Bladderwrack. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Cystistatin by Ortho Molecular Products

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 5 of its 5 active ingredients.
  • No proprietary blends here — you can verify the dose of every single component.

Cystistatin contains 5 active ingredients: marshmallow, celery seed extract, berberine hydrochloride hydrate, uva ursi leaf extract, and bladderwrack. The product also includes inactive ingredients (vegetable capsule, magnesium stearate, and silicon dioxide) used as fillers and binders.

Each ingredient is included for urinary tract or related support, though the evidence backing them varies—some have insufficient data, while berberine shows possibly effective evidence for conditions like high cholesterol and diabetes.

Does it work?

Leans against
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Leans against

The strongest graded evidence we hold for the stated purpose leans against a benefit.

Why this rating?
  • The label markets this product for: Urinary tract and bladder health support.
  • We looked for evidence on: Urinary tract infections (UTIs), urinary discomfort, bladder support, kidney health.
  • The closest evidence on file: Uva Ursi is rated "Possibly Ineffective" for Urinary tract infections (UTIs) (Natural Medicines).
  • Also on file: Celery is rated "Insufficient Reliable Evidence To Rate" for Urinary tract infections (UTIs).

The evidence supporting these ingredients is limited. Berberine is rated possibly effective for high cholesterol, blood sugar control, high blood pressure, PCOS, and H. pylori infection.

For the other ingredients, the data we hold shows insufficient evidence: marshmallow's effectiveness for vaginal yeast infections, diarrhea, and other conditions hasn't been reliably established, and celery seed extract likewise lacks solid evidence for sexual function, mood, headache, or metabolic support. Uva ursi is actually rated possibly ineffective for urinary tract infections, the condition it's traditionally used for.

The evidence, ingredient by ingredient Marshmallow Celery Berberine Uva Ursi Fucus Vesiculosus

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 4 of the 5 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 5 of 5.
  • General safety write-ups exist for 5 of 5.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Berberine, marshmallow, celery seed, and uva ursi are generally well tolerated for short-term use, though safety data are limited for most. The most common side effects of berberine are digestive (abdominal pain, diarrhea, nausea, constipation) and occasionally dizziness or fatigue.

Uva ursi can cause nausea, vomiting, diarrhea, and stomach upset; at high doses it may cause serious effects like convulsions and delirium. Celery may trigger photosensitivity reactions or allergic responses, including oral allergy syndrome and, rarely, anaphylaxis in sensitive people.

Marshmallow is generally well tolerated but human safety data are limited. During pregnancy, avoid this product: berberine should be avoided (it may cross the placenta and harm the fetus), celery seed should be avoided in medicinal amounts, uva ursi should be avoided (it may stimulate the uterus), and marshmallow lacks enough safety data.

While breastfeeding, berberine passes into milk and should be avoided, and celery seed and uva ursi are best avoided due to insufficient information.

Side effects, ingredient by ingredient Marshmallow Celery Berberine Uva Ursi Fucus Vesiculosus

Meds to double-check

Major interaction found
Known Interaction Concern · database check
Major identified

At least one ingredient has a documented Major-severity interaction. Check your medications for a personalized result.

Why this rating?
  • 5 of the 5 matched ingredients can interact with medications — Uva Ursi, Fucus Vesiculosus, Marshmallow, Celery, Berberine.
  • The most serious interaction on file is rated Major.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; immunosuppressants / transplant drugs; diabetes medications; lithium.
  • For scale: 2,181 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Check your medications carefully before taking Cystistatin. The Major concern is cyclosporine (an immunosuppressant)—berberine can dangerously raise its levels.

Moderate-severity interactions affect blood thinners and antiplatelet drugs, diabetes medications, blood pressure drugs, thyroid medication (levothyroxine), the antidepressant venlafaxine, and many drugs metabolized by your liver's cytochrome P450 system (especially CYP3A4, CYP2D6, and CYP2C9). Additionally, lithium levels may be affected by marshmallow, celery, or uva ursi.

Use the search tool on this page to verify every prescription and over-the-counter medication you take.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with graded evidence leaning against its stated purpose. Major medication interactions have been identified, and safety information is well characterized.

Cystistatin is intended for urinary tract support, but berberine's interactions with many medications—especially cyclosporine—and the product's effects on drug metabolism make it risky for anyone on prescription drugs. If you take blood thinners, diabetes medications, thyroid medication, blood pressure drugs, or medications metabolized by the liver, talk to your pharmacist before starting this.

Pregnant or breastfeeding people should avoid it entirely.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 5 of 5 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Apr 25, 2018.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Cystistatin, straight from the product label.

Brand Ortho Molecular Products
Barcode (UPC) 615033015619
Net contents 60 Capsule(s)
Market status On market
Date entered into DSLD Apr 25, 2018
DSLD ID 174721
Product type Other Combinations
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years)
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Cystistatin by Ortho Molecular Products, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Capsule(s)
Maximum serving Sizes:
2 Capsule(s)
Servings per container
30
UPC/BARCODE
615033015619
IngredientAmount% DV
Marshmallow150 mg--
Celery seed extract80 mg--
Berberine Hydrochloride Hydrate200 mg--
Uva Ursi leaf extract650 mg--
Bladderwrack80 mg--

Other ingredients: natural Vegetable Capsules, Magnesium Stearate, Silicon Dioxide

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
General Statements

Professional Strength: Not for sale through Amazon.com

Learn more

Immune health

Suggested/Recommended/Usage/Directions

Suggested Use: 1-2 capsules three times per day or as recommended by your health care professional.

Formulation

Formulated To Be Free Of Allergens Derived From: Gluten, yeast, artificial colors and flavors.

Precautions

Do not consume this product if you are pregnant or nursing. Consult your physician for further information.

As with all dietary supplements, some individuals may not tolerate or may be allergic to the ingredients used. Please read the ingredient panel carefully prior to ingestion. Cease taking this product and consult your physician if you have negative reactions upon ingestion.

Keep out of reach of children.

This product was sealed for your protection. Do not use if outer logoed neck seal or inner-seal is missing or damaged.

Do not accept if label shows signs of tampering

Storage

Keep container tightly closed. Store at room temperature.

FDA Disclaimer Statement

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

General

Product #561060 Label ID L-OMP100-561060-K V3

Seals/Symbols

Vcaps

Brand IP Statement(s)

VitaSecure

Because efficacy matters

FDA Statement of Identity

Dietary Supplement

See for yourself

Cystistatin by Ortho Molecular Products label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Cystistatin by Ortho Molecular Products

These are the 5 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Capsule(s) Dosage formCapsule Servings per container30 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Marshmallow

Interacts with
2,040 drugs
150 mg per serving

Marshmallow root is a traditional herb rich in soothing, gel-like fibers called mucilage, which is why it has long been used for coughs, sore throats,...

Marshmallow monograph & interactions

Celery seed extract

Interacts with
651 drugs
80 mg per serving

Celery is a common vegetable that is also taken as a seed extract or oil supplement, mainly for blood pressure, fluid retention, and joint discomfort....

Celery seed extract monograph & interactions

Berberine Hydrochloride Hydrate

Interacts with
1,160 drugs
200 mg per serving

Berberine is a yellow plant compound that has shown promise for lowering blood sugar and cholesterol in some studies, but the quality of research vari...

Berberine Hydrochloride Hydrate monograph & interactions

Uva Ursi leaf extract

Interacts with
803 drugs
650 mg per serving Form: Arbutin

Uva ursi is a traditional herb used mainly for urinary tract infections, and its leaves contain a compound called arbutin that may have antimicrobial...

Uva Ursi leaf extract monograph & interactions

Bladderwrack

Interacts with
891 drugs
80 mg per serving

Fucus vesiculosus (bladderwrack) is a brown seaweed rich in iodine that has been used traditionally for thyroid concerns, weight, and skin. There is l...

Bladderwrack monograph & interactions

Other (inactive) ingredients: Natural Vegetable Capsules, Magnesium Stearate, Silicon Dioxide. These complete the product’s ingredient list but are not active constituents.

Interaction report

Cystistatin by Ortho Molecular Products Drug Interactions

Want to check YOUR meds against Cystistatin?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
2,180Drugs
1 Major 1,239 Moderate 940 Minor

Ingredients driving the most interactions

Marshmallow 2,040

Each ingredient & the kinds of drugs it affects

For each ingredient in Cystistatin with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Marshmallow3 drug types · 2,040 drugs

Lithium

Theoretically, due to potential diuretic effects, marshmallow might reduce excretion and increase levels of lithium.
Marshmallow is thought to have diuretic properties. To avoid lithium toxicity, the dose of lithium might need to be decreased when used with marshmallow.

Likelihood Probable Evidence D
Anticoagulant/Antiplatelet Drugs

Theoretically, marshmallow flower might have antiplatelet effects.
Animal research suggests that marshmallow flower extract has antiplatelet effects. However, the root and leaf of marshmallow, not the flower, are the plant parts most commonly found in dietary supplements. Theoretically, use of marshmallow flower with anticoagulant/antiplatelet drugs can have additive effects, and might increase the risk for bleeding in some patients.

Likelihood Unlikely Evidence D
Oral Drugs

Theoretically, mucilage in marshmallow might impair absorption of oral drugs.
Marshmallow contains mucilage which can affect oral drug absorption. To avoid changes in absorption, take marshmallow 30-60 minutes after oral medications.

Likelihood Possible Evidence D

Berberine Hydrochloride Hydrate15 drug types · 1,160 drugs

Cyclosporine (Neoral, Sandimmune)

Berberine can increase serum levels of cyclosporine.
Berberine can reduce metabolism and increase serum levels of cyclosporine. Berberine might inhibit cytochrome P450 3A4 (CYP3A4), which metabolizes cyclosporine.

Likelihood Probable Evidence A
Anticoagulant/Antiplatelet Drugs

Theoretically, berberine might increase the risk of bleeding when used with anticoagulant or antiplatelet drugs.
In vitro and in vivo research suggest that berberine can inhibit platelet aggregation. Theoretically, berberine might have additive effects when used with anticoagulant and antiplatelet drugs and increase the risk of bleeding.

Likelihood Possible Evidence D
Antidiabetes Drugs

Theoretically, berberine may increase the risk of hypoglycemia when taken with antidiabetes drugs.
Clinical research shows that berberine may lower blood glucose levels. Theoretically, berberine might have additive effects with antidiabetes drugs and increase the risk of hypoglycemia.

Likelihood Possible Evidence D
Antihypertensive Drugs

Theoretically, berberine might have additive effects with antihypertensive drugs.
Animal research suggests that berberine can have hypotensive effects. Also, a clinical study suggests that taking berberine in combination with amlodipine can lower systolic and diastolic blood pressure when compared with amlodipine alone.

Likelihood Possible Evidence D
Cns Depressants

Theoretically, berberine might increase the sedative effects of CNS depressants.
Animal research suggests that berberine may have sedative effects. Theoretically, use of berberine along with CNS depressants might produce additive therapeutic and adverse effects.

Likelihood Possible Evidence D
Cytochrome P450 2C9 (Cyp2C9) Substrates

Theoretically, berberine might increase serum levels of drugs metabolized by CYP2C9.
Preliminary clinical research shows that berberine can inhibit CYP2C9. Theoretically, taking berberine with drugs metabolized by CYP2C9 might increase drug levels and increase the risk of adverse effects.

Likelihood Possible Evidence B
Cytochrome P450 2D6 (Cyp2D6) Substrates

Theoretically, berberine might increase serum levels of drugs metabolized by CYP2D6.
In vitro research and preliminary clinical evidence show that berberine can inhibit CYP2D6. Theoretically, use of berberine with drugs metabolized by CYP2D6 might increase drug levels and increase the risk of adverse effects.

Likelihood Possible Evidence B
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, berberine might increase serum levels of drugs metabolized by CYP3A4.
In vitro research and preliminary clinical research show that berberine moderately inhibits CYP3A4. Theoretically, use of berberine with drugs metabolized by CYP3A4 might increase drug levels and increase the risk of adverse effects.

Likelihood Possible Evidence A
Dextromethorphan (Robitussin Dm, Others)

Theoretically, berberine may increase serum levels of dextromethorphan.
Preliminary clinical research shows that berberine can inhibit cytochrome P450 2D6 (CYP2D6) activity and reduce the metabolism of dextromethorphan. This may increase the effects and side effects of dextromethorphan.

Likelihood Possible Evidence B
Losartan (Cozaar)

Berberine might reduce the therapeutic effects of losartan by decreasing its conversion to its active form.
Preliminary clinical research suggests that berberine can inhibit cytochrome P450 2C9 (CYP2C9) activity and reduce metabolism of losartan.

Likelihood Possible Evidence B
Metformin (Glucophage)

Theoretically, berberine might increase the therapeutic and adverse effects of metformin.
In vitro and animal studies show that berberine can increase the systemic exposure and half-life of metformin, potentially increasing metformin's effects and side effects. This interaction seems to be most apparent when berberine is administered 2 hours prior to metformin. Taking berberine and metformin at the same time does not appear to increase systemic exposure to metformin.

Likelihood Possible Evidence D
Midazolam (Versed)

Berberine can reduce metabolism of midazolam, which might increase the risk of severe adverse effects.
Preliminary clinical research shows that berberine can inhibit cytochrome P450 3A4 (CYP3A4) activity and reduce metabolism of midazolam.

Likelihood Possible Evidence B
Pentobarbital (Nembutal)

Berberine might increase the sedative effect of pentobarbital.
Evidence from animal research shows that berberine can prolong pentobarbital-induced sleeping time. Theoretically, combining berberine and pentobarbital might increase the sedative effects of pentobarbital.

Likelihood Possible Evidence D
Tacrolimus (Prograf)

Berberine has been associated with increased blood levels of tacrolimus.
In a 16-year-old patient with idiopathic nephrotic syndrome who was being treated with tacrolimus 6.5 mg twice daily, intake of berberine 200 mg three times daily increased the blood concentration of tacrolimus from 8 to 22 ng/mL. Following a reduction of the tacrolimus dose to 3 mg daily, blood levels of tacrolimus decreased to 12 ng/mL.

Likelihood Possible Evidence D
Acetazolamide

Laboratory studies and initial clinical findings suggest that berberine has the potential to increase acetazolamide concentrations in the body. More research is needed to confirm this interaction.

Likelihood Possible Evidence C

Bladderwrack9 drug types · 891 drugs

Amiodarone (Cordarone)

Theoretically, combining Fucus vesiculosus with amiodarone might cause excessively high iodine levels.
Fucus vesiculosus contains high concentrations of iodine. Amiodarone contains 37.3% iodine and can increase iodine levels. Concomitant use might increase the risk of having excessive iodine levels and adversely affecting thyroid function. Monitor thyroid function.

Likelihood Probable Evidence D
Antithyroid Drugs

Due to its iodine content, Fucus vesiculosus might alter the effects of antithyroid drugs.
Fucus vesiculosus contains high concentrations of iodine. Iodine in high doses has been reported to cause both hyperthyroidism and hypothyroidism, depending on the individual's past medical history. Taking Fucus vesiculosus while using antithyroid drugs could alter the effects of the antithyroid drugs.

Likelihood Possible Evidence D
Lithium

Concomitant use of Fucus vesiculosus and lithium has resulted in hyperthyroidism.
There is a case of hyperthyroidism occurring in a patient taking Fucus vesiculosus and lithium. Monitor thyroid hormones closely in patients taking lithium and Fucus vesiculosus concomitantly.

Likelihood Possible Evidence D
Thyroid Hormone

Due to its iodine content, Fucus vesiculosus might alter the effects of thyroid hormone.
Fucus vesiculosus contains high concentrations of iodine. Iodine in high doses has been reported to cause both hyperthyroidism and hypothyroidism, depending on the individual's past medical history. Taking Fucus vesiculosus while using thyroid hormone could alter the effects of thyroid hormone.

Likelihood Possible Evidence D
Anticoagulant/Antiplatelet Drugs

Theoretically, taking Fucus vesiculosus with antiplatelet or anticoagulant drugs might increase the risk of bruising and bleeding.
In vitro evidence suggests that a constituent of Fucus vesiculosus, known as fucoidan, has anticoagulant effects. However, in clinical research, fucoidan does not seem to have significant anticoagulant activity when taken orally, possibly due to poor absorption.

Likelihood Unlikely Evidence D
Cytochrome P450 2C8 (Cyp2C8) Substrates

Theoretically, concomitant use of Fucus vesiculosus with CYP2C8 substrates might increase the risk for adverse effects.
In vitro research shows that fucoidan, a constituent of Fucus vesiculosus, inhibits CYP2C8. This interaction has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2C9 (Cyp2C9) Substrates

Theoretically, concomitant use of Fucus vesiculosus with CYP2C9 substrates might increase the risk for adverse effects.
In vitro research shows that fucoidan, a constituent of Fucus vesiculosus, inhibits CYP2C9. This interaction has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2D6 (Cyp2D6) Substrates

Theoretically, concomitant use of Fucus vesiculosus with CYP2D6 substrates might alter the effects of these substrates.
In vitro research shows that fucoidan, a constituent of Fucus vesiculosus, both inhibits and induces CYP2D6. This interaction has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, concomitant use of Fucus vesiculosus with CYP3A4 substrates might increase the risk for adverse effects.
In vitro research shows that fucoidan, a constituent of Fucus vesiculosus, inhibits CYP3A4. This interaction has not been reported in humans.

Likelihood Possible Evidence D

Uva Ursi leaf extract6 drug types · 803 drugs

Cytochrome P450 2C19 (Cyp2C19) Substrates

Theoretically, uva ursi may decrease the metabolism of CYP2C19 substrates.
In vitro, uva ursi appears to inhibit cytochrome CYP2C19. This effect has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, uva ursi may decrease the metabolism of CYP3A4 substrates.
In vitro, uva ursi appears to inhibit CYP3A4. This effect has not been reported in humans.

Likelihood Possible Evidence D
Glucuronidated Drugs

Theoretically, uva ursi may increase levels of drugs metabolized by glucuronidation.
In vitro, uva ursi extract appears to strongly inhibit UDP-glucuronosyltransferase (UGT) 1A1 (UGT1A1). However, uva ursi extract does not appear to inhibit UGT1A1 in animal models. This effect has not been reported in humans.

Likelihood Possible Evidence D
Lithium

Theoretically, uva ursi may increase lithium levels, necessitating a decrease in dose.
Uva ursi may have diuretic properties. Diuretics may increase lithium reabsorption with sodium in the proximal tubule of the kidney. Theoretically, uva ursi might reduce excretion and increase levels of lithium.

Likelihood Probable Evidence D
Urinary Acidifying Agents

Effects of uva ursi in the urinary tract may be reduced by urinary acidifying agents.
Uva ursi seems to work best in alkaline urine. Theoretically, taking uva ursi with medications known to acidify the urine may decrease any effects of uva ursi on the urinary tract.

Likelihood Possible Evidence D
P-Glycoprotein Substrates

Theoretically, uva ursi may alter the levels of drugs transported by P-glycoprotein.
In vitro, uva ursi appears to inhibit the multi-drug transporter protein, P-glycoprotein. This effect has not been reported in humans.

Likelihood Possible Evidence D

Celery seed extract8 drug types · 651 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, celery root might increase the risk of bleeding when taken with anticoagulant/antiplatelet drugs.
Celery root contains the constituents falcarinol and falcarindiol. Laboratory research suggests that these constituents can inhibit platelet aggregation. This effect has not been reported in humans.

Likelihood Possible Evidence D
Antihypertensive Drugs

Theoretically, celery seed extract might have additive effects with antihypertensive drugs.
Clinical research suggests that taking celery seed extract may reduce daytime systolic blood pressure by about 12 mmHg compared to less than 1 mmHg with placebo.

Likelihood Probable Evidence B
Cytochrome P450 1A2 (Cyp1A2) Substrates

Theoretically, celery might increase levels of drugs metabolized by CYP1A2.
In vitro and animal research suggests that constituents of celery can inhibit CYP1A2. This effect has not been reported in humans.

Likelihood Possible Evidence D
Levothyroxine (Synthroid, Others)

Theoretically, celery seed might decrease the effects of levothyroxine.
Several cases of hypothyroidism with low T4 levels have been reported in people who were previously stabilized on levothyroxine and then started taking celery seed tablets. They presented with symptoms such as lethargy, bloating, and dry skin, and recovered when celery seed was stopped. However, celery stem and leaf has been associated with case reports of hyperthyroidism in patients with no pre-existing thyroid disorders.

Likelihood Possible Evidence D
Lithium

Theoretically, celery might reduce excretion and increase levels of lithium due to potential diuretic effects.
Celery is thought to have diuretic properties. However, this effect has not been confirmed in humans.

Likelihood Probable Evidence D
Venlafaxine (Effexor)

Theoretically, celery root extract might increase blood levels of venlafaxine.
There is one case report of a patient who experienced medication-induced bipolar disorder after beginning to take celery root extract 1000 mg daily along with venlafaxine 75 mg and St. John's wort 600 mg daily. Symptoms included confusion, speech abnormalities, manic affect, and visual hallucinations. The plasma level of venlafaxine was 476.8 ng/mL (normal range 195-400 ng/mL). It is theorized that celery root increased venlafaxine levels by inhibiting cytochrome P450 2D6.

Likelihood Possible Evidence D
Acetaminophen (Tylenol, Others)

Theoretically, celery juice might increase the effects and side effects of acetaminophen.
Animal research suggests that concomitant use of celery juice plus acetaminophen prolongs the effects of acetaminophen. This effect has been attributed to a decrease in hepatic cytochrome P450 activity. However, other animal research shows that pretreatment with celery root extract protects against acetaminophen-induced acute liver failure. These effects have not been reported in humans.

Likelihood Possible Evidence D
Photosensitizing Drugs

Theoretically, celery might increase the risk of photosensitivity reactions when taken with photosensitizing drugs.
Laboratory research shows that celery contains photosensitizing agents such as phenols and psoralens.

Likelihood Possible Evidence D
The maker

Brand information

Manufacturer and brand details for Cystistatin, from the product label.

Ortho Molecular Products

See all Ortho Molecular Products products
Name
Ortho Molecular Products, Inc.
Street Address
1991 Duncan Place
City
Woodstock
State
IL
ZipCode
60098
Web Address
OrthoMolecularProducts.com
Pharmacist Counseling Corner

Cystistatin by Ortho Molecular Products: Common Questions

Does Cystistatin by Ortho Molecular Products interact with any medications?
Yes. Based on its ingredients, Cystistatin has a known interaction with 2,180 medications, including 1 rated major. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Cystistatin contains 5 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I take this while pregnant or breastfeeding?
No. Berberine should be avoided during pregnancy (it may harm the fetus) and breastfeeding (it passes into milk). Celery seed in medicinal amounts and uva ursi should also be avoided in pregnancy, and marshmallow lacks enough safety data. This product is not appropriate for either situation—talk with your doctor about safe alternatives.
What are the most common side effects?
Digestive upset is most likely: berberine commonly causes abdominal pain, diarrhea, nausea, and constipation. Celery may cause photosensitivity (sun sensitivity) or, in sensitive people, allergic reactions like itching in the throat. Uva ursi can cause nausea, vomiting, and diarrhea. Most people tolerate these ingredients short-term, but if your stomach is sensitive, start with a low dose.
Is this product proven to work for urinary tract infections?
Not reliably. Uva ursi, one of the main ingredients, is actually rated possibly ineffective for UTIs in the data we hold. Marshmallow and celery seed lack solid evidence for urinary tract support. While berberine shows promise for several conditions like blood sugar and cholesterol, evidence for urinary tract health specifically is insufficient.
What is berberine and why is it in here?
Berberine is an alkaloid (a plant compound) with antimicrobial and anti-inflammatory properties. It's included for its potential benefits on blood sugar, cholesterol, and general metabolic support, though in this product it's part of a broader blend. It does have the most serious interaction concerns in the formula.
Can this interfere with my other medications?
Very likely, especially if you take blood thinners, diabetes drugs, blood pressure medications, thyroid medication, or any antidepressant. Berberine inhibits liver enzymes that break down many drugs, potentially raising their levels and side effects. You must check your specific medications with the tool on this page before starting—do not skip this step.
Why do I need to space this 30–60 minutes away from my other oral medications?
Marshmallow contains mucilage (a gel-like substance) that can physically coat your digestive tract and slow the absorption of other oral medications. Taking your other drugs 30–60 minutes before this supplement helps ensure they're absorbed properly and work as intended.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Cystistatin is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Cystistatin label
Go deeper

The Full Monographs Behind Cystistatin’s Ingredients

Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.

Sources

Sources & How We Checked

Cystistatin's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 117 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Marshmallow 5 references
  1. Monographs on the medicinal uses of plant drugs. Exeter, UK: European Scientific Co-op Phytother, 1997.
  2. Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics. 2nd ed. New York, NY: John Wiley & Sons, 1996.
  3. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.
  4. Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
  5. Hage-Sleiman R, Mroueh M, Daher CF. Pharmacological evaluation of aqueous extract of Althaea officinalis flower grown in Lebanon. Pharm Biol 2011;49(3):327-33.

See these in context on the Marshmallow monograph →

Celery 48 references
  1. Newall CA, Anderson LA, Philpson JD. Herbal Medicine: A Guide for Healthcare Professionals. London, UK: The Pharmaceutical Press, 1996.
  2. The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.
  3. Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
  4. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000;57:1221-7. DOI
  5. Gral N, Beani JC, Bonnot D, et al. [Plasma levels of psoralens after celery ingestion]. Ann Dermatol Venereol 1993;120:599-603.
  6. Moses, G. Thyroxine interacts with celery seed tablets? Australian Prescriber 2001;24:6-7. DOI
  7. Ciganda C, and Laborde A. Herbal infusions used for induced abortion. J Toxicol.Clin Toxicol. 2003;41:235-239. PubMed
  8. Jakovljevic, V., Raskovic, A., Popovic, M., and Sabo, J. The effect of celery and parsley juices on pharmacodynamic activity of drugs involving cytochrome P450 in their metabolism. Eur.J Drug Metab Pharmacokinet. 2002;27(3):153-156. PubMed
  9. Wang, L., Sterling, B., and Don, P. Berloque dermatitis induced by "Florida water". Cutis 2002;70(1):29-30.
  10. Weber, I. C., Davis, C. P., and Greeson, D. M. Phytophotodermatitis: the other "lime" disease. J Emerg.Med 1999;17(2):235-237. PubMed
  11. Rueff, F., Eberlein-Konig, B., and Przybilla, B. Oral hyposensitization with celery juice. Allergy 2001;56(1):82-83. PubMed
  12. Lombaert, G. A., Siemens, K. H., Pellaers, P., Mankotia, M., and Ng, W. Furanocoumarins in celery and parsnips: method and multiyear Canadian survey. J AOAC Int 2001;84(4):1135-1143. DOI
  13. Ballmer-Weber, B. K., Hoffmann, A., Wuthrich, B., Luttkopf, D., Pompei, C., Wangorsch, A., Kastner, M., and Vieths, S. Influence of food processing on the allergenicity of celery: DBPCFC with celery spice and cooked celery in patients with celery allergy PubMed
  14. Hoerler, S. and Ukiwe, J. Laryngeal edema from celery allergic reaction. Am.J.Emerg.Med. 1992;10(6):613. PubMed
  15. DeLeo, V. A. Photocontact dermatitis. Dermatol Ther 2004;17(4):279-288. PubMed
  16. Groot, B. J., Belinfante-van Gelder, M. E., and Jans, H. W. [An epidemic of dermatitis caused by blanched celery]. Ned.Tijdschr.Geneeskd. 6-20-1992;136(25):1210-1213.
  17. Erdmann, S. M., Sachs, B., Schmidt, A., Merk, H. F., Scheiner, O., Moll-Slodowy, S., Sauer, I., Kwiecien, R., Maderegger, B., and Hoffmann-Sommergruber, K. In vitro analysis of birch-pollen-associated food allergy by use of recombinant allergens in the b
  18. Jeanmougin, M., Varroud-Vial, C., and Dubertret, L. [Phototoxic side-effect following celery ingestion during puvatherapy]. Ann.Dermatol Venereol 2005;132(6-7 Pt 1):566-567.
  19. Christensen, L. P. and Brandt, K. Bioactive polyacetylenes in food plants of the Apiaceae family: occurrence, bioactivity and analysis. J Pharm.Biomed.Anal. 6-7-2006;41(3):683-693. PubMed
  20. Gorgus, E., Lohr, C., Raquet, N., Guth, S., and Schrenk, D. Limettin and furocoumarins in beverages containing citrus juices or extracts. Food Chem.Toxicol. 2010;48(1):93-98. PubMed
  21. Maso, M. J., Ruszkowski, A. M., Bauerle, J., DeLeo, V. A., and Gasparro, F. P. Celery phytophotodermatitis in a chef. Arch.Dermatol. 1991;127(6):912-913. DOI
  22. Ljunggren, B. Severe phototoxic burn following celery ingestion. Arch.Dermatol. 1990;126(10):1334-1336. DOI
  23. Held, J. L. Phytophotodermatitis. Am Fam.Physician 1989;39(4):143-146.
  24. Silverstein, S. R., Frommer, D. A., Dobozin, B., and Rosen, P. Celery-dependent exercise-induced anaphylaxis. J.Emerg.Med. 1986;4(3):195-199. PubMed
  25. Rose, M. H. and Altman, L. C. Anaphylaxis after ingestion of raw celery. Ann.Allergy 1985;54(2):166.
  26. Forsbeck, M. and Ros, A. M. Anaphylactoid reaction to celery. Contact Dermatitis 1979;5(3):191. PubMed
  27. DeChamp, C., Michel, J., Deviller, P., and Perrin, L. F. [Anaphylactic shock to celery and sensitization to ragweed and mugwort. Crossed or concomitant allergy?]. Presse Med. 3-31-1984;13(14):871-874.
  28. Johansson, S. G., Dannaeus, A., and Lilja, G. The relevance of anti-food antibodies for the diagnosis of food allergy. Ann.Allergy 1984;53(6 Pt 2):665-672.
  29. Beier, R. C., Ivie, G. W., Oertli, E. H., and Holt, D. L. HPLC analysis of linear furocoumarins (psoralens) in healthy celery (Apium graveolens). Food Chem.Toxicol. 1983;21(2):163-165. PubMed
  30. Kidd, J. M., III, Cohen, S. H., Sosman, A. J., and Fink, J. N. Food-dependent exercise-induced anaphylaxis. J Allergy Clin Immunol 1983;71(4):407-411. PubMed
  31. Moneret-Vautrin, D. A. and Kanny, G. [Food-induced anaphylaxis. A new French multicenter survey]. Ann.Gastroenterol Hepatol (Paris) 1995;31(4):256-263.
  32. Bonnin, J. P., Grezard, P., Colin, L., and Perrot, H. [A very significant case of allergy to celery]. Allerg.Immunol.(Paris) 1995;27(6):209.
  33. Bonnin, J. P., Grezard, P., Colin, L., and Perrot, H. [A very significant case of allergy to celery cross-reacting with ragweed]. Allerg.Immunol.(Paris) 1995;27(3):91-93.
  34. Moneret-Vautrin, D. A. and Kanny, G. [Food-induced anaphylaxis. A new French multicenter study]. Bull.Acad.Natl.Med 1995;179(1):161-184.
  35. Puig, L. and de Moragas, J. M. Enhancement of PUVA phototoxic effects following celery ingestion: cool broth also can burn. Arch.Dermatol. 1994;130(6):809-810. DOI
  36. Egan, C. L. and Sterling, G. Phytophotodermatitis: a visit to Margaritaville. Cutis 1993;51(1):41-42.
  37. Boffa, M. J., Gilmour, E., and Ead, R. D. Celery soup causing severe phototoxicity during PUVA therapy. Br.J.Dermatol. 1996;135(2):334.
  38. Wuthrich, B., Borga, A., and Yman, L. Oral allergy syndrome to a jackfruit (Artocarpus integrifolia). Allergy 1997;52(4):428-431.
  39. Peterson, S., Lampe, J. W., Bammler, T. K., Gross-Steinmeyer, K., and Eaton, D. L. Apiaceous vegetable constituents inhibit human cytochrome P-450 1A2 (hCYP1A2) activity and hCYP1A2-mediated mutagenicity of aflatoxin B1. Food Chem.Toxicol. 2006;44(9):147 PubMed
  40. Baek CH, Bae YJ, Cho YS, Moon HB, Kim TB. Food-dependent exercise-induced anaphylaxis in the celery-mugwort-birch-spice syndrome. Allergy. 2010;65(6):792-3. PubMed
  41. Khalid Z, Osuagwu FC, Shah B, Roy N, Dillon JE, Bradley R. Celery root extract as an inducer of mania induction in a patient on venlafaxine and St John's Wort. Postgrad Med. 2016;128(7):682-3. PubMed
  42. Palgan K, Götz-Zbikowska M, Tykwinska M, Napiórkowska K, Bartuzi Z. Celery-cause of severe anaphylactic shock. Postepy Hig Med Dosw (Online). 2012;66:132-4.
  43. Maljaei MB, Moosavian SP, Mirmosayyeb O, Rouhani MH, Namjoo I, Bahreini A. Effect of celery extract on thyroid function; is herbal therapy safe in obesity? Int J Prev Med 2019;10:55. doi: 10.4103/ijpvm.IJPVM_209_17. PubMed
  44. Rouhi-Boroujeni H, Hosseini M, Gharipour M, Rouhi-Boroujeni H. Is herbal therapy safe in obesity? A case of Apium graveolens (Celery) induced hyperthyroidism. ARYA Atheroscler 2016;12(5):248-9.
  45. Emad AM, Ali SF, Abdel-Rahman EA, et al. Anti-inflammatory and antioxidant effects of Apium graveolens L. extracts mitigate against fatal acetaminophen-induced acute liver toxicity. J Food Biochem 2020:e13399. Online ahead of print.
  46. Shayani Rad M, Moohebati M, Mohajeri SA. Effect of celery (Apium graveolens) seed extract on hypertension: A randomized, triple-blind, placebo-controlled, cross-over, clinical trial. Phytother Res 2022.
  47. Azimi M, Zahedi MJ, Raeiszadeh M, Iraji A, Cramer H, Pasalar M. Efficacy and Safety of a Persian Medicine Formula on Functional Dyspepsia Symptoms: A Randomized Double-Blind Active-Control Clinical Trial. Complement Med Res 2023;30(3):238-247. PubMed
  48. Ukleja-Sokolowska N, Lis K, Graczyk M, Bartuzi M, Bartuzi Z. The use of inhibition assay in Api g 7 suspected allergy in a female patient with anaphylaxis: A case report. Int J Immunopathol Pharmacol 2024;38:3946320231223004. PubMed

See these in context on the Celery monograph →

Berberine 41 references
  1. Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonate 1993;63:201-8. PubMed
  2. Janbaz KH, Gilani AH. Studies on preventive and curative effects of berberine on chemical-induced hepatotoxicity in rodents. Fitoterapia 2000;71:25-33.. PubMed
  3. Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol 2005;61:567-72. PubMed
  4. Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008;93:2559-65. PubMed
  5. Huang XS, Yang GF, Pan YC. Effect of berberin hydrochloride on blood concentration of cyclosporine A in cardiac transplanted patients. Zhongguo Zhong Xi Yi Jie He Za Zhi 2008;28:702-4.
  6. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7:273-82. PubMed
  7. Chatterjee P, Franklin MR. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 2003;31:1391-7. PubMed
  8. Marin-Neto, J. A., Maciel, B. C., Secches, A. L., and Gallo, Junior L. Cardiovascular effects of berberine in patients with severe congestive heart failure. Clin.Cardiol. 1988;11(4):253-260. PubMed
  9. Choudhry, V. P., Sabir, M., and Bhide, V. N. Berberine in giardiasis. Indian Pediatr. 1972;9(3):143-146.
  10. Shanbhag, S. M., Kulkarni, H. J., and Gaitonde, B. B. Pharmacological actions of berberine on the central nervous system. Jpn.J Pharmacol 1970;20(4):482-487. PubMed
  11. Wu, J. F. and Liu, T. P. [Effects of berberine on platelet aggregation and plasma levels of TXB2 and 6-keto-PGF1 alpha in rats with reversible middle cerebral artery occlusion]. Yao Xue.Xue.Bao. 1995;30(2):98-102.
  12. Peng, W. H., Hsieh, M. T., and Wu, C. R. Effect of long-term administration of berberine on scopolamine-induced amnesia in rats. Jpn J Pharmacol 1997;74(3):261-266. DOI
  13. Sharda DC. Berberine in the treatment of diarrhoea of infancy and childhood. J Indian M A 1970;54(1):22-24.
  14. Sabir M and Bhide NK. Study of some pharmacological actions of berberine. Ind J Physiol & Pharmac 1971;15(3):111-132.
  15. Tripathi YB and Shukla SD. Berberis artistata inhibits PAF induced aggregation of rabbit platelets. Phytotherapy Research 1996;10:628-630.
  16. Seery TM and Bieter RN. A contribution to the pharmacology of berberine. J Pharmacol Exp Ther 1940;69:64-67. DOI
  17. Xin, H. W., Wu, X. C., Li, Q., Yu, A. R., Zhong, M. Y., and Liu, Y. Y. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find.Exp.Clin Pharmacol 2006;28(1):25-29.
  18. Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., Ren, G., and Ning, G. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol.Metab 2008;93(7):2559-2565. PubMed
  19. Yin, J., Xing, H., and Ye, J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008;57(5):712-717. PubMed
  20. Zhang, H., Wei, J., Xue, R., Wu, J. D., Zhao, W., Wang, Z. Z., Wang, S. K., Zhou, Z. X., Song, D. Q., Wang, Y. M., Pan, H. N., Kong, W. J., and Jiang, J. D. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin re
  21. Guo, Y., Chen, Y., Tan, Z. R., Klaassen, C. D., and Zhou, H. H. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol 2012;68(2):213-217. PubMed
  22. Wei, W., Zhao, H., Wang, A., Sui, M., Liang, K., Deng, H., Ma, Y., Zhang, Y., Zhang, H., and Guan, Y. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndro
  23. Marazzi, G., Cacciotti, L., Pelliccia, F., Iaia, L., Volterrani, M., Caminiti, G., Sposato, B., Massaro, R., Grieco, F., and Rosano, G. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. PubMed
  24. Meng, S., Wang, L. S., Huang, Z. Q., Zhou, Q., Sun, Y. G., Cao, J. T., Li, Y. G., and Wang, C. Q. Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention. Clin Exp.Pharmacol Physiol 2012;39 PubMed
  25. Hermann, R. and von, Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med 2012;78(13):1458-1477. PubMed
  26. Chun YT, Yip TT, Lau KL, and et al. A biochemical study on the hypotensive effect of berberine in rats. Gen Pharmac 1979;10:177-182. PubMed
  27. Saksena HC, Tomar VN, and Soangra MR. Efficacy of a new salt of Berberine Uni-Berberine in oriental sore. Current Medical Practice 1970;14:247-252.
  28. Abascal K, Yarnell E. Recent clinical advances with berberine. Altern Complement Ther 2010;16(5):281-7. DOI
  29. Dong H, Zhao Y, Zhao L, Lu F. The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med 2013;79(6):437-46. PubMed
  30. Hou Q, Han W, Fu X. Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome. Eur J Clin Pharmacol 2013;69(10):1861-2. PubMed
  31. Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69-81. PubMed
  32. Li G, Zhao M, Qiu F, Sun Y, Zhao L. Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects. Drug Des Devel Ther. 2018;13:129-139. PubMed
  33. Ju J, Li J, Lin Q, Xu H. Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. Phytomedicine. 2018;50:25-34. PubMed
  34. Xu L, Zhang Y, Xue X, et al. A phase I trial of berberine in Chinese with ulcerative colitis. Cancer Prev Res (Phila). 2020;13(1):117-26. PubMed
  35. Lyu Y, Zhang Y, Yang M, et al. Pharmacokinetic interactions between metformin and berberine in rats: Role of oral administration sequences and microbiota. Life Sci. 2019;235:116818. PubMed
  36. Chen YX, Gao QY, Zou TH, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol Hepatol. 2020;5(3):267-75. PubMed
  37. Zhang J, Wang Y, Jiang H, et al. Preventive effect of berberine on postoperative atrial fibrillation. Circ Arrhythm Electrophysiol 2022;15(10):e011160. PubMed
  38. Blais JE, Huang X, Zhao JV. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs 2023;83(5):403-427. PubMed
  39. Panigrahi A, Mohanty S. Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial. BMC Endocr Disord 2023;23(1):190. PubMed
  40. Nie Q, Li M, Huang C, et al. The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review. J Transl Med 2024;22(1):225. PubMed
  41. Koperska A, Moszak M, Seraszek-Jaros A, Bogdanski P, Szulinska M. Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled tr

See these in context on the Berberine monograph →

Uva Ursi 8 references
  1. Newall CA, Anderson LA, Philpson JD. Herbal Medicine: A Guide for Healthcare Professionals. London, UK: The Pharmaceutical Press, 1996.
  2. Schulz V, Hansel R, Tyler VE. Rational Phytotherapy: A Physician's Guide to Herbal Medicine. Terry C. Telger, transl. 3rd ed. Berlin, GER: Springer, 1998.
  3. Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
  4. Wang L, Del Priore LV. Bull's-eye maculopathy secondary to herbal toxicity from uva ursi. Am J Ophthalmol 2004;137:1135-7. PubMed
  5. Beaux, D., Fleurentin, J., and Mortier, F. Effect of extracts of Orthosiphon stamineus Benth, Hieracium pilosella L., Sambucus nigra L. and Arctostaphylos uva-ursi (L.) Spreng. in rats. Phytother.Res 1999;13(3):222-225.
  6. de Arriba SG, Naser B, Nolte KU. Risk assessment of free hydroquinone derived from Arctostaphylos Uva-ursi folium herbal preparations. Int J Toxicol. 2013;32(6):442-453.
  7. Park JB, Kim D, Min JS, et al. Identification and characterization of in vitro inhibitors against UDP-glucuronosyltransferase 1A1 in uva-ursi extracts and evaluation of in vivo uva-ursi-drug interactions. Food Chem Toxicol. 2018;120:651-661. PubMed
  8. Chauhan B, Yu C, Krantis A, et al. In vitro activity of uva-ursi against cytochrome P450 isoenzymes and P-glycoprotein. Can J Physiol Pharmacol. 2007;85(11):1099-107.

See these in context on the Uva Ursi monograph →

Fucus Vesiculosus 15 references
  1. Goodman GA, Rall TW, Nies AS, Taylor P. The Pharmacological Basis of Therapeutics, 9th ed.
  2. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press, 2002.
  3. Phaneuf D, Cote I, Dumas P, et al. Evaluation of the contamination of marine algae (Seaweed) from the St. Lawrence River and likely to be consumed by humans. Environ Res 1999;80:S175-S182. PubMed
  4. Durig J, Bruhn T, Zurborn KH, et al. Anticoagulant fucoidan fractions from Fucus vesiculosus induce platelet activation in vitro. Thromb Res 1997;85:479-91. PubMed
  5. Conz PA, La Greca G, Benedetti P, et al. Fucus vesiculosus: a nephrotoxic alga? Nephrol Dial Transplant 1998;13:526-7.
  6. Ohye H, Fukata S, Kanoh M, et al. Thyrotoxicosis caused by weight-reducing herbal medicines. Arch Intern Med 2005;165:831-4. PubMed
  7. Okamura K, Inoue K, Omae T. A case of Hashimoto's thyroiditis with thyroid immunological abnormality manifested after habitual ingestion of seaweed. Acta Endocrinol (Copenh) 1978;88:703-12. PubMed
  8. Agarwal SC, Crook JR, Pepper CB. Herbal remedies -- how safe are they? A case report of polymorphic ventricular tachycardia/ventricular fibrillation induced by herbal medication used for obesity. Int J Cardiol 2006;106:260-1. PubMed
  9. Sterling JB, Heymann WR. Potassium iodide in dermatology: a 19th century drug for the 21st century-uses, pharmacology, adverse effects, and contraindications. J Am Acad Dermatol 2000;43:691-7. PubMed
  10. Catania, M. A., Oteri, A., Caiello, P., Russo, A., Salvo, F., Giustini, E. S., Caputi, A. P., and Polimeni, G. Hemorrhagic cystitis induced by an herbal mixture. South.Med.J. 2010;103(1):90-92. PubMed
  11. Cumashi, A., Ushakova, N. A., Preobrazhenskaya, M. E., D'Incecco, A., Piccoli, A., Totani, L., Tinari, N., Morozevich, G. E., Berman, A. E., Bilan, M. I., Usov, A. I., Ustyuzhanina, N. E., Grachev, A. A., Sanderson, C. J., Kelly, M., Rabinovich, G. A., I
  12. Irhimeh, M. R., Fitton, J. H., and Lowenthal, R. M. Pilot clinical study to evaluate the anticoagulant activity of fucoidan. Blood Coagul.Fibrinolysis 2009;20(7):607-610. PubMed
  13. Arbaizar, B. and Llorca, J. [Fucus vesiculosus induced hyperthyroidism in a patient undergoing concomitant treatment with lithium]. Actas Esp.Psiquiatr. 2011;39(6):401-403.
  14. Church FC, Meade JB, Treanor RE, and et al. Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin. J Biol Chem 2-25-1989;264(6):3618-3623. DOI
  15. Mathew L, Burney M, Gaikwad A, et al. Preclinical evaluation of safety of fucoidan extracts from Undaria pinnatifida and Fucus vesiculosus for use in cancer treatment. Integr Cancer Ther 2017;16(4):572-84.

See these in context on the Fucus Vesiculosus monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring